Compare Dyne Therapeutics Inc. Common Stock (DYN) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs MobilEye Global Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while MobilEye Global Inc trades at $7.1 (market cap $5.97B). The key difference: MobilEye Global Inc is far larger — about 2.1× Dyne Therapeutics Inc. Common Stock's market cap, and MobilEye Global Inc is more actively traded (6,124,531 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and MobilEye Global Inc for 15 Days on average.
| DYN | MBLY | |
|---|---|---|
Market Cap | $2.86B | $5.97B |
Volume | 3,341,579 | 6,124,531 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $15.33 |
52-Week Low | $14.60 | $6.56 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $2.18B | $4.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Mobileye Global (MBLY) trades at $7.02, up 2.63% with recent earnings beats but faces bearish technical signals and significant net losses. The stock shows strong institutional support with 57.7% analyst buy ratings and a $10.77 consensus target, yet profitability remains challenged with a -201.5% net margin. Recent news highlights ADAS business momentum and autonomous vehicle expansion opportunities.
The outlook presents a high-risk opportunity with potential upside from autonomous driving adoption, but investors face substantial execution risks and ongoing losses. Key catalysts include Porsche launch progress and robotaxi developments, while competitive pressures and cash flow volatility remain significant concerns for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
